LPCN

Business Context and Reporting Period

Lipocine Inc. (LPCN) is a clinical-stage biopharmaceutical company focused on developing oral delivery solutions for difficult-to-deliver molecules using its proprietary Lip'ral platform. The company's primary commercial asset is TLANDO, an oral testosterone replacement therapy (TRT) approved by the FDA in March 2022. The reporting period covers the fiscal year ended December 31, 2024.

During 2024, Lipocine transitioned commercial rights for TLANDO in the U.S. and Canada from Antares Pharma to Verity Pharmaceuticals (effective February 1, 2024). Additionally, the company secured new licensing agreements for TLANDO in South Korea (SPC Korea) and the Gulf Cooperation Council (Pharmalink).

Key Financial Metrics

Note: 2023 revenue reflects a significant reversal of variable consideration related to the terminated Antares agreement.

Material Changes vs. Prior Period

• Revenue Turnaround: The company shifted from a $2.9 million revenue reversal in 2023 to $11.2 million in revenue in 2024. This was driven by $10.0 million in upfront license fees from Verity Pharmaceuticals and $298,000 in royalties.
• Profitability: Lipocine reported a net income of approximately $8,000 in 2024, a stark contrast to the $16.4 million net loss in 2023. This was achieved through reduced R&D spend and significant licensing revenue.
• R&D Reduction: R&D expenses decreased by $2.8 million (28%) year-over-year, primarily due to the completion of the LPCN 1148 Phase 2 study in 2023 and reduced TLANDO-related costs.
• Licensing Strategy: The company successfully replaced its U.S./Canada licensee (Antares) with Verity and expanded into South Korea and the GCC, securing upfront payments and future royalty streams.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Liquidity: Management believes existing capital resources ($21.6 million) are sufficient to fund operations through at least March 31, 2026.
• Pipeline Priorities: The company is advancing LPCN 1154 (oral brexanolone for postpartum depression), with a Phase 3 safety and efficacy study expected to begin in Q2 2025. Other candidates include LPCN 2401 (obesity), LPCN 1148 (cirrhosis), and LPCN 1144 (MASH).
• Commercialization: Future revenue depends heavily on Verity's commercialization of TLANDO in the U.S. and Canada, as well as regulatory approvals for TLANDO in South Korea and the GCC in 2025.

Risks and Contingencies

• Capital Requirements: The company will need to raise additional capital after March 2026 to continue clinical development. Failure to do so could force a reduction in operations.
• Regulatory Uncertainty: The FDA requires an additional efficacy and safety study for LPCN 1154 before NDA submission. There is no guarantee of approval for any pipeline candidates.
• Third-Party Dependence: Revenue from TLANDO is contingent on the commercial success of licensees (Verity, SPC, Pharmalink). Lipocine has limited control over their marketing efforts.
• Competition: The TRT market is competitive with multiple oral, injectable, and gel options. The PPD market now includes ZURZUVAE (zuranolone).

Investor Verification Checklist

• Licensee Performance: Monitor Verity Pharmaceuticals' sales performance of TLANDO to assess future royalty revenue potential.
• Cash Runway: Verify the company's ability to raise capital before March 2026 to avoid operational disruption.
• LPCN 1154 Progress: Track the initiation and results of the required Phase 3 study for postpartum depression, as this is a key value driver.
• Regulatory Filings: Watch for marketing approval applications in South Korea and the GCC, expected in 2025.
• Stock Dilution: Review the status of the A.G.P. "at-the-market" sales agreement for potential equity dilution.